- Home
- AIHS vs PRTG Comparison
AIHS vs PRTG Comparison
Compare AIHS & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIHS
- PRTG
- Stock Information
- Founded
- AIHS 2014
- PRTG 1973
- Country
- AIHS China
- PRTG British Virgin Islands
- Employees
- AIHS N/A
- PRTG N/A
- Industry
- AIHS Finance: Consumer Services
- PRTG Oil & Gas Production
- Sector
- AIHS Finance
- PRTG Energy
- Exchange
- AIHS Nasdaq
- PRTG Nasdaq
- Market Cap
- AIHS 9.5M
- PRTG 8.1M
- IPO Year
- AIHS 2018
- PRTG N/A
- Fundamental
- Price
- AIHS $0.88
- PRTG $4.57
- Analyst Decision
- AIHS
- PRTG
- Analyst Count
- AIHS 0
- PRTG 0
- Target Price
- AIHS N/A
- PRTG N/A
- AVG Volume (30 Days)
- AIHS 13.9K
- PRTG 129.9K
- Earning Date
- AIHS 02-14-2025
- PRTG 03-03-2025
- Dividend Yield
- AIHS N/A
- PRTG N/A
- EPS Growth
- AIHS N/A
- PRTG N/A
- EPS
- AIHS N/A
- PRTG N/A
- Revenue
- AIHS $5,878,700.00
- PRTG N/A
- Revenue This Year
- AIHS N/A
- PRTG N/A
- Revenue Next Year
- AIHS N/A
- PRTG N/A
- P/E Ratio
- AIHS N/A
- PRTG N/A
- Revenue Growth
- AIHS 12.21
- PRTG N/A
- 52 Week Low
- AIHS $0.70
- PRTG $2.10
- 52 Week High
- AIHS $1.45
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- AIHS 46.48
- PRTG 48.57
- Support Level
- AIHS $0.87
- PRTG $4.46
- Resistance Level
- AIHS $1.03
- PRTG $5.00
- Average True Range (ATR)
- AIHS 0.07
- PRTG 0.61
- MACD
- AIHS -0.00
- PRTG 0.00
- Stochastic Oscillator
- AIHS 6.06
- PRTG 50.00
About AIHS Senmiao Technology Limited
Senmiao Technology Ltd is a holding company. The company's operating segment includes Automobile Transaction and Related Services focusing on the online ride-hailing industry in the People's Republic of China and Online ride-hailing platform Services through its own platform, Xixingtianxia. It generates maximum revenue from the Automobile Transaction and Related Services segment. Geographically, it derives revenue from China.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.